

## NEW CHALCONE DERIVATIVES AS ANTICANCER AND ANTIOXIDANT AGENTS: SYNTHESIS, MOLECULAR DOCKING STUDY AND BIOLOGICAL EVALUATION

Nabeel A. Abdul-Rida<sup>\*</sup>, Kawther M. Talib

Department of Chemistry, College of Science, University of Al-Qadisiyha,  
Diwanyiah, 58002, Iraq

\*Email: [nabeel.a.alradha@qu.edu.iq](mailto:nabeel.a.alradha@qu.edu.iq), [Kawthertallib196@gmail.com](mailto:Kawthertallib196@gmail.com)

Received 18.12.2023

Accepted 16.02.2024

**Abstract:** In this approach, a series of new chalcone derivatives bearing baclofen drug were synthesized via Claisen-Schmidt condensation and evaluated in vitro as anticancer and antioxidant agents. The newly synthesized compounds were characterized by FT-IR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR spectra, and elemental analysis. All products were screened in vitro against both cell lines HdFn and MCF-7. The cytotoxicity assay results revealed that derivatives **5a** and **5d** exhibited good inhibition for cell lines MCF-7 with IC<sub>50</sub> values 32.5 and 37.6 μM, respectively while **5a** and **5c** exhibited acceptable inhibition for HdFn with IC<sub>50</sub> values 76.7 and 78.6 μM, respectively, compared to the Tamoxifen drug. Molecular docking study of the target compounds confirmed the results of the cytotoxicity test. In addition, results of the DPPH investigation revealed good antioxidant activity for derivatives **5a**, **5c** and **5d** with inhibition percentages 86.62, 81.38, and 76.42%, respectively, compared to ascorbic acid.

**Keyword:** Chalcone, Anticancer, Antioxidant, Molecular Docking, Cytotoxicity

### Introduction

Cancer is a deadly disease that still threatens human lives despite scientific progress and continuous attempts to develop a mechanism to control and prevent the disease. Therefore, many researches and recent studies have sought to find an effective strategic treatment that meets the ambitions of the world [1]. Many synthesized chemical compounds have shown various biological activities [2-9]. Among those compounds, chalcones and their derivatives have received increasing attention from researchers because of their various activities, such as anti-bacterial [10-12], anti-fungal [13, 14], anti-cancer [15-17], anti-Alzheimer [18, 19], anti-inflammatory [20, 21], and antioxidant [22-24], in addition to their importance in the industrial field [25-27].

In this work, we created a number of chalcones combined with the baclofen drug and studied their anti-cancer and antioxidant activity, as well as studying their molecular docking.

### Experimental part

#### General information

All the chemicals and solvents were obtained from commercial suppliers and were used as received without further purification. Melting points remained uncorrected and were determined on the Symmetric Multiprocessing (SMP) device (Gallenkamp). Fourier-transform infrared (FT-IR) spectra were recorded with FT-IR spectrophotometer (Bruker). Nuclear magnetic resonance (NMR) measurements (<sup>1</sup>H NMR, <sup>13</sup>C NMR) were measured on Bruker AMX 400 and 100 instruments using tetramethylsilane (TMS) as a reference and DMSO-*d*<sub>6</sub> as a solvent. Analytical thin-layer chromatography (TLC) was carried out on Merck plates 60 F254 (0.2 mm thick). Microelements (C.H.N.) were analysed using a VEA3000 device (Shimadzu, Japan).

## Synthesis

### Synthesis of the 3-(4'-acetyl-[1,1'-biphenyl]-4-yl)-4-aminobutanoic acid **2** [28]

A mixture of 4-amino-3-(4-chlorophenyl) butanoic acid **1** (1 mmol), (4-acetylphenyl) boronic acid **2** (1 mmol), Pd(0)(pph<sub>3</sub>) (40 mg), sodium carbonate (5 ml) in propanol (15 ml) was refluxed for 12h, and the reaction was monitored by TLC. After the reaction completion, the reaction mixture was cooled to room temperature and poured over crushed ice with stirring. The result precipitate was collected by filtration, washed with cold water, dried and recrystallized from appropriate solvents to give target compounds good yields. The solid obtained was purified with flash chromatography using methanol–dichloromethane (8:2). Physical state **3**: Orange crystals; yield is 88%; m.p. 178-180°C. FT-IR (KBr, cm<sup>-1</sup>):  $\nu$  3354 (OH), 3212 (N-H), 1732, 1685 (C=O), 1572 (C=C). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>, ppm):  $\delta$  12.41 (s, 1H, OH), 8.05-7.11 (d, 8H, H-arom.), 3.54 (d, 2H, CH<sub>2</sub>CO), 3.28 (s, 1H, NH<sub>2</sub>), 2.64 (d, 2H, CH<sub>2</sub>N), 2.11 (s, 3H, Me), 1.78-170 (m, 1H, CH<sub>tertiary</sub>). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>, ppm):  $\delta$  197.3 (COOH), 177.1 (C=O), 137.6-121.3 (C-arom.), 42.1 (CH<sub>2</sub>-N), 36.2 (CH<sub>2</sub>-CO), 34.1 (C-<sub>tertiary</sub>), 26.2 (Me). Analytical calculated for C<sub>18</sub>H<sub>19</sub>NO<sub>3</sub>: C, 72.71; H, 6.44; N, 4.71. Found: C, 72.11; H, 5.74; N, 4.01.

### General procedure for the synthesis of the chalcone derivatives **5a-d** [15]

Aldehydes **4a-d** (2 mmol) were individually dissolved with the derivative **3** (2 mmol) in 30 mL of ethanol and refluxed for 6-8h in the presence of piperidine as a catalyst. After the reaction completion (TLC check), the reaction mixture was cooled to room temperature, washed with brine solution, and then extracted with chloroform three times. The organic extract obtained was dried and concentrated into a solid under a vacuum. The products obtained were purified with flash chromatography using methanol–dichloromethane (8:2).

**4-Amino-3-(4'-(3-(4-hydroxyphenyl)acryloyl)-[1,1'-biphenyl]-4-yl)butanoic acid **5a**:** light red crystals, yield 78%, m.p 190-192°C. FT-IR (KBr, cm<sup>-1</sup>):  $\nu$  3368 (OH), 3185 (N-H), 1737, 1674 (C=O), 1615 (C=C). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>, ppm):  $\delta$  12.03 (s, 1H, OH), 8.25-7.24 (d, 12H, H-arom.), 3.36 (d, 2H, CH<sub>2</sub>CO), 3.22 (s, 1H, NH<sub>2</sub>), 2.52 (d, 2H, CH<sub>2</sub>N) 1.94-184 (m, 1H, CH<sub>tertiary</sub>). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>, ppm):  $\delta$  177.2 (C=O), 135.1-123.4 (C-arom.), 39.6 (CH<sub>2</sub>-N), 36.5 (CH<sub>2</sub>-CO), 31.2 (C-<sub>tertiary</sub>). Analytical calculated for C<sub>25</sub>H<sub>23</sub>NO<sub>4</sub>: C, 74.80; H, 5.77; N, 3.49. Found: C, 74.2; H, 5.17; N, 2.89.

**4-Amino-3-(4'-(dimethylamino)phenyl)acryloyl)-[1,1'-biphenyl]-4-yl)butanoic acid **5b**:** Dark yellow crystals, yield 64%, m.p 203-205°C. FT-IR (KBr, cm<sup>-1</sup>):  $\nu$  3375 (OH), 3194 (N-H), 1729, 1678 (C=O), 1608 (C=C). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>, ppm):  $\delta$  12.35 (s, 1H, OH), 8.24-7.31 (d, 12H, H-arom.), 3.28 (d, 2H, CH<sub>2</sub>CO), 3.14 (s, 1H, NH<sub>2</sub>), 2.41 (d, 2H, CH<sub>2</sub>N) 1.82-175 (m, 1H, CH<sub>tertiary</sub>). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>, ppm):  $\delta$  175.8 (C=O), 133.6-118.7 (C-arom.), 41.8 (CH<sub>2</sub>-N), 37.7 (CH<sub>2</sub>-CO), 32.8 (C-<sub>tertiary</sub>). Analytical calculated for C<sub>27</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub>: C, 75.68; H, 6.59; N, 6.54. Found: C, 75.08; H, 5.99; N, 5.94.

**4-Amino-3-(4'-(3-(4-nitrophenyl)acryloyl)-[1,1'-biphenyl]-4-yl)butanoic acid **5c**:** brown crystals, yield 68%, m.p 225-227°C. FT-IR (KBr, cm<sup>-1</sup>):  $\nu$  3386 (OH), 3176 (N-H), 1732, 1675 (C=O), 1624 (C=C). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>, ppm):  $\delta$  12.42 (s, 1H, OH), 8.19-7.26 (d, 12H, H-arom.), 3.16 (d, 2H, CH<sub>2</sub>CO), 3.02 (s, 1H, NH<sub>2</sub>), 2.35 (d, 2H, CH<sub>2</sub>N) 1.94-186 (m, 1H, CH<sub>tertiary</sub>). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>, ppm):  $\delta$  177.3 (C=O), 138.2-120.6 (C-arom.), 43.5 (CH<sub>2</sub>-N), 38.1 (CH<sub>2</sub>-CO), 33.5 (C-<sub>tertiary</sub>). Analytical calculated for C<sub>25</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub>: C, 69.76; H, 5.15; N, 6.51. Found: C, 69.16; H, 4.55; N, 5.91.

**4-Amino-3-(4'-(3-(4-hydroxy-3-methoxyphenyl)acryloyl)-[1,1'-biphenyl]-4-yl)butanoic acid **5d**:** Dark red crystals, yield 79%, m.p 212-215°C. FT-IR (KBr, cm<sup>-1</sup>):  $\nu$  3423 (OH), 3183 (N-H), 1734, 1670 (C=O), 1611 (C=C). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>, ppm):  $\delta$  12.63, 9.65 (s, 1H, OH), 8.15-7.34 (d, 4H, H-arom.), 3.84 (s, 3H, OCH<sub>3</sub>), 3.23 (d, 2H, CH<sub>2</sub>CO), 3.05 (s, 1H, NH<sub>2</sub>), 2.18 (d, 2H, CH<sub>2</sub>N) 1.88-178 (m, 1H, CH<sub>tertiary</sub>). <sup>13</sup>C-NMR (DMSO-*d*<sub>6</sub>, ppm):  $\delta$  192.3 (C=O), 176.4 (COOH), 153.5 (C-O), 132.5-122.6 (C-arom.), 56.12 (C-O), 44.8 (CH<sub>2</sub>-N), 37.4 (CH<sub>2</sub>-CO), 32.7 (C-<sub>tertiary</sub>). Analytical calculated for C<sub>26</sub>H<sub>25</sub>NO<sub>5</sub>: C, 72.37; H, 5.84; N, 3.25. Found: C, 71.77; H, 5.24; N, 2.65.

### The cytotoxicity assay [29]

The cytotoxic activities of derivatives **5a–d** were investigated *in vitro* against two human cancer cell lines (HdFn, MCF-7) using the MTT test. The cell cultures, 100  $\mu\text{L}$  of  $2 \times 10^4$  cells/mL in DMEM (Dulbecco's Modified Eagle's medium) containing 10% FBS (fetal bovine serum), were seeded in polystyrene microplates (96-well flat-bottom) and incubated at  $37^\circ\text{C}$  for 24h in 5%  $\text{CO}_2$  humidified atmosphere. Next, different concentrations of derivatives **5a–d** (10, 20, 40, 60, and 80  $\mu\text{M}$ ) were added to the plate and then incubated for 48 h. After that, the old medium was replaced and a solution of MTT (50  $\mu\text{L}$  of 0.5 mg/mL in DMEM) was added to each well in the plate and then incubated for another 4 h. The formazan crystals obtained were solubilized by adding 100  $\mu\text{L}$  of DMSO to each well. The solution absorbance obtained was determined at 570 nm on an ELISA microplate reader. The mean percentage of cell viability was calculated from the data obtained. A triplicate of experiments was performed for each test.

#### Antioxidant assay [30]

The antioxidant effect of compounds **5a–d** was evaluated *in vitro* using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay. Practically, a solution of DPPH (60  $\mu\text{M}$ ) in 2ml of ethanol was individually added to different concentrations of derivatives **5a–d** (12.5, 25, 50, 100, 250, and 500 $\mu\text{M}$ ), and then the homogenized mixture was incubated in the dark for 30 min. After that, the absorbance of the solution was determined at wavelength 515 nm on a UV/Vis spectrophotometer Amersham Biospectro. The results obtained were compared with ascorbic acid and used to calculate the percentage of reduction of the DPPH. The percentage of inhibition was calculated using the following formula:

$$\% \text{ of antioxidant activity} = [(A_C - A_S) \div A_C] \times 100$$


Where:  $A_C$  is absorbance of the control;  $A_S$  is absorbance of the sample.

#### Docking study analysis [31]

Four of the synthesized compounds underwent molecular docking studies and the target is to identify the potential binding with the estrogen receptor alpha ( $\text{ER}\alpha$ ) with ID 3ERT obtained from PDB page <https://www.rcsb.org/>. The selected derivatives were sketched in 2D and converted into 3D using molecular mechanics and then used as ligands. Autodock 4.2.6 program was used in calculating the result of the docking analysis as binding energy. Discovery Studio software was employed to set the receptor and shown the binding modes as 2D interaction poses.

## Results and Discussion


According to the Suzuki-Mayura coupling reaction, 3-(4'-acetyl-[1,1'-biphenyl]-4-yl)-4-aminobutanoic acid was synthesized from reaction 4-amino-3-(4-chlorophenyl)butanoic acid **1** (Baclofen) with (4-acetylphenyl)boronic acid **2** using a palladium catalyst and a base as sodium carbonate, as shown in **Scheme 1**.



**Scheme 1. Synthesis of compound 3 by Suzuki-Mayura coupling reaction**

In the next step, the derivative **3** was reacted with some aromatic aldehydes **4a–d** in the presence of piperidine as a catalyst to synthesize chalcone derivatives **5a–d** according to the Claisen-Schmidt condensation mechanism, as shown in **Scheme 2**. The structures of all synthesized

compounds were spectroscopically characterized by (IR,  $^1\text{H}$  NMR,  $^{13}\text{C}$  NMR) as well as micro-elements analysis. The spectroscopic data obtained were included in the **Experimental part**.




**Scheme 2.** The experimental steps for synthesis of compounds **5a-d**

## Biological activity

### Cytotoxicity of synthesized compounds

The four derivatives **5a-d** were screened *in vitro* for evaluation of their antitumor activities against two cancer cell lines HdFn and MCF-7 by the standard MTT method and using Tamoxifen drug as a positive control. The percentages of cell viability of the compounds **5a** and **5d** are shown in Fig.1.



**Fig. 1.** Cell viability percentage of compounds **5c** and **5d** against two cancer cell lines HdFn and MCF-7.

The cytotoxicity results of derivatives **5a-d** against HdFn and MCF-7 were compared with the activity of Tamoxifen and presented as  $\text{IC}_{50}$  in **Table 1**. According to the results, found that some of the tested derivatives exhibited good inhibitory activity. Among those derivatives, **5a** and **5d** showed anti-proliferative effects against MCF-7 cells with an  $\text{IC}_{50}$  value of 32.5 and 37.6  $\mu\text{M}$ , respectively. For of HdFn cells, derivatives **5a** and **5c** showed acceptable cytotoxicity in comparison with the activity of Tamoxifen, while the other derivatives exhibited poor cytotoxic activity. Generally, the results of this test are preliminary evidence that calls on researchers to conduct many tests to use these derivatives as therapeutic agents in the future.

**Table 1.** The cytotoxicity results for synthesized compounds **5a-d** against HdFn and MCF-7 cancer cell lines in comparison to the Tamoxifen drug.

Compounds	$\text{IC}_{50}\mu\text{M}\pm\text{SD}$	
	HdFn	MCF-7
<b>5a</b>	$76.7 \pm 3.24$	$32.5 \pm 1.25$

<b>5b</b>	> 200	86.4±4.11
<b>5c</b>	78.6 ± 3.95	> 200
<b>5d</b>	88.6 ± 4.16	37.6 ± 1.31
<b>Tamoxifen</b>	36 ± 1.14	30 ± 1.02

### Antioxidant activity study

The antioxidant activity of new compounds **5a-d** was tested using a DPPH assay. The ascorbic acid is used as a reference for comparison. The test mechanism depends on using hydrogen donor antioxidants for the reduction of the DPPH radical solution and formation of the DPPH-H. Generally, the tested compounds showed potent activity as antioxidants according to the results obtained in **Table 2**. At a concentration of 500 µM, found that the % inhibition of **5a**, **5c** and **5d** potency of 86.62, 81.38, and 76.42%, respectively. These results revealed that compounds **5a**, **5c** and **5d** have the most potent levels of activity compared to that of standard ascorbic acid and this may be due to their structural properties that help in capturing free radicals.

**Table 2. Results of DPPH assay of derivatives 5a-d at wavelength 515 nm and concentration 500 µM.**

Compounds	Absorbance of Sample	% Inhibition
<b>5a</b>	<b>0.063</b>	<b>86.62±4.81</b>
<b>5b</b>	<b>0.214</b>	<b>32.64±1.39</b>
<b>5c</b>	<b>0.071</b>	<b>81.38±4.21</b>
<b>5d</b>	<b>0.104</b>	<b>76.42±4.05</b>
Ascorbic-acid	0.065	86.24±4.76

### Molecular Docking study

A molecular docking of derivatives 5a-d was studied *in silico* and the aim is to justify their biological activity. A derivatives **5a-d** were docked as ligands with the receptor ERα (PDB: 3ERT). According to the docking results, the binding energy of derivatives **5a-d** were -9.26, -7.34, -3.7 and -8.81 [kcal/mol], respectively. The results obtained revealed that the derivatives 5a, 5c, and 5d bound with the active site of the protein selectively by various interactions such as hydrophobic, electrostatic interactions and hydrogen bonds. The binding pose of **5a**, **5c** and **5d** with the active pocket in the protein was shown as 2D representations in **Fig.2**. The binding energies and types of interactions are shown in **Table 3**.




Fig. 2. 2D conformations for simulation of 5a-d with the active site of the target protein

Table 3. Docking results, the binding energy and types of interactions of derivatives 5a-d with the catalytic site of the target protein.

Compound	Ligand moiety	Site(A.A)	Interaction	E (kcal/mol)
5a	NH <sub>2</sub>	GLU 758 (A)	H- Bond	-9.26
	OH	LEU 861(A)	H- Bond	
	6-ring	LEU 861(A)	Pi-Alkyl	
		LYS 860(A)	Pi-Alkyl	
	C=O	ARG 836(A)	H-Bond	
		Other	Electrostatic	
5b	NH <sub>2</sub>	PRO 699(A)	H- Bond	-7.34
	N-(Me) <sub>2</sub>	LEU 777(A)	H- Bond	
	6-ring	ALA 702(A)	Pi-Alkyl	
		ILE 1018(A)	Pi-Alkyl	
	C=O	ARG 831(A)	H-Bond	
		Other	Electrostatic	
5c	NH <sub>2</sub>	ALI 886(A)	H- Bond	-3.7
	C=O	LYS 875(A)	H- Bond	
	6-ring	PRO 877(A)	Pi-Alkyl	
		VAL 876(A)	Pi-Alkyl	
		VAL 876(A)	Pi-Sigma	
		Other	Electrostatic	
5d	OH	TYR 827(A)	H- Bond	-8.81
	NH <sub>2</sub>	GLN 1020 (A)	H-Bond	
	6-ring	ALA 702(A)	Pi-Sigma	
		LEU 703(A)	Pi-Alkyl	
		ARG 705(A)	Pi-Alkyl	
		Other	Electrostatic	



## Conclusions

A series of chalcone derivatives bearing baclofen drug were synthesized via Claisen-Schmidt condensation and biologically evaluated *in vitro* as anticancer and antioxidant agents. The results of the cytotoxicity assay indicated the possibility of using the compounds 4-Amino-3-(4'-(3-(4-hydroxyphenyl)acryloyl)-[1,1'-biphenyl]-4-yl)butanoic acid **5a** and 4-Amino-3-(4'-(3-(4-hydroxy-3-methoxyphenyl)acryloyl)-[1,1'-biphenyl]-4-yl)butanoic acid **5d** as antiproliferative agents of cell lines MCF-7. In the DPPH test, results obtained revealed good antioxidant activity of some new chalcone derivatives.

## Acknowledgements

The authors are thankful to the Department of Chemistry – College of Science – University of Al Qadisiyah for providing facilities.

## References

1. Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piñeros M., Znaor A., Soerjomataram I., Bray F., Global Cancer Observatory: Cancer Today // International Agency for Research on Cancer. 2020, (<https://gco.iarc.fr/today>, accessed February 2021).
2. Abdul-Rida N.A., Tarrad I.H. Design, Synthesis, Molecular Docking Study, and Biological Evaluation of Some New 1,2,3-Triazole Derivatives as Anticancer and Antioxidant Agents // *Russ J Gen Chem.*, 2023, 93, p.2874. doi.org/10.1134/S107036322311018X
3. Abdul-Rida N.A., Adnan S., Jaber Q.A.H. Development of Novel Imaging Fluorescent Agents Bearing Anti-Inflammatory Drugs: Synthesis, Structural Characterization and Evaluation of Biological Activity // *Russ. J. Bioorg. Chem.*, 2020, 46, p. 620. doi:10.1134/S1068162020040032
4. Nabeel Z., Jaber Q.A.H., Abdul-Rida N.A. Novel Benzo[f]coumarin Derivatives as Probable Acetylcholinesterase Inhibitors: Synthesis, *In Vitro*, and *In Silico* Studies for Evaluation of Their Anti-AChE Activity // *Indones. J. Chem.*, 2022, 22(1), p.35–46. doi:10.22146/ijc.65663
5. Al-Radha N.A.A., Jaber Q.A.H. Synthesis of Some Substituted Pyrimidines Derived from 3-Acetyl Coumarin // *Asian J. Chem.*, 2015, 27, p. 3687. doi:10.14233/ajchem.2015.18925
6. Huseynov K., Aliyev P., Mirzoyeva M.A., Eyvazova I.M., Aliyev N.A. Synthesis of Alkoxy carbonylmethyl Esters of Thioacetic and Thiobenzoic Acids and Their Investigation as Additives to Lubricating Oils // *Chemical Problems*, 2023, 3 (21), p. 294. DOI: 10.32737/2221-8688-2023-3-294-300
7. Nabeel A.A.R., Islam H.T. Synthesis Characterization *in Silico* and *in Vitro* Study of New 1, 2, 3-Triazole Derivatives as Antioxidant Agents // *Chemical Problems*, 2023, 21(4), p. 343. doi:10.32737/2221-8688-2023-4-343-352
8. Jaber Q.A., Shentaif A.H., Almajidi M. *et al.* Synthesis, Structure, and *In Vitro* Pharmacological Evaluation of some New Pyrimidine-2-Sulfonamide Derivatives and Their Molecular Docking Studies on Human Estrogen Receptor Alpha and CDK2/Cyclin Proteins // *Russ J Bioorg. Chem.*, 2023, 49, p. S106. doi.org/10.1134/S1068162023080095
9. Vahabova V.A. Synthesis and Radical Polymerization of Benzamidmetacrylate // *Chemical Problems*, 2023, 1 (21), p. 78. DOI: 10.32737/2221-8688-2023-1-78-84
10. Abdul-Reda N.A., Abd A.S. A Study of Some New Chalcone Derivatives from Cholic Acid Based on Synthesis, Characterization, and Biological Activity // *Novel Aspects on Chemistry and Biochemistry*, 2023, 7, p. 98. <https://doi.org/10.9734/bpi/nacb/v7/6792A>
11. Abdul-Reda N.A., S. Abd, A. Synthesis, Characterization and Biological Activity of Some Chalcone Derivatives of Cholic Acid // *Asian J Chem.*, 2018, 30(11), p. 2577. <https://doi.org/10.14233/ajchem.2018.21666>
12. Al-Masoudi N.A., Kadhim R.A., Abdul-Rida N.A., Saeed B.A., Engel M. New biaryl-chalcone derivatives of pregnenolone via Suzuki–Miyaura cross-coupling reaction. Synthesis,

- CYP17hydroxylase inhibition activity, QSAR, and molecular dock-ing study // *Steroids* 2015, 101, p. 43–50. [doi.org/10.1016/j.steroids.2015.05.011](https://doi.org/10.1016/j.steroids.2015.05.011)
13. Abdul-Reda N.A., Abdul-Ameer S.R. Synthesis, Identification and Biological Activity of Some New Chalcone derivatives from 8-Chlorotheophylline // *Orient J Chem.*, 2018, 34(1). <http://dx.doi.org/10.13005/ojc/340144>
  14. Shukurov C.Y., Synthesis and Biological Activity of New Dithiocarbamate Derivatives // *Chemical Problems*, 2020 no. 2 (18), p. 174. DOI: [10.32737/2221-8688-2020-2-174-180](https://doi.org/10.32737/2221-8688-2020-2-174-180)
  15. Jaber Q.A.H., Abdul-Rida N.A., Adnan S. Boosting 3*H*-Benzo[*f*]chromen-3-one Chalcone with Anti-inflammatory Drugs: Synthesis, Characterization, and Evaluation of Cytotoxicity and Antimicrobial Activity // *Russ. J. Org. Chem.*, 2020, 56, p.1622. [doi:10.1134/S1070428020090195](https://doi.org/10.1134/S1070428020090195)
  16. Marquina S., Maldonado-Santiago M., Sanchez-Carranza J.N., Antunez-Mojica M., Gonzalez-Maya L., Razo-Hernandez R.S., Alvarez L. Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway // *Bioorg. Med. Chem.* 2019, 27, p. 43. [doi: 10.1016/j.bmc.2018.10.045](https://doi.org/10.1016/j.bmc.2018.10.045).
  17. Zhou W., Zhang W., Peng Y., Jiang Z.-H., Zhang L., Du Z. Design, Synthesis and Anti-Tumor Activity of Novel Benzimidazole-Chalcone Hybrids as Non-Intercalative Topoisomerase II Catalytic Inhibitors // *Molecules*. 2020, 25, p.3180. [doi: 10.3390/molecules25143180](https://doi.org/10.3390/molecules25143180).
  18. Thapa P., Upadhyay S.P., Suo W.Z., Singh V., Gurung P., Lee E.S., Sharma R., Sharma M. Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease // *Bioorg Chem.* 2021, 108, p. 104681. [doi: 10.1016/j.bioorg.2021.104681](https://doi.org/10.1016/j.bioorg.2021.104681).
  19. Thamban C.N., Fosso M.Y., Tsodikov O.V., LeVine I.H., Garneau S. Combining Chalcones with Donepezil to Inhibit Both Cholinesterases and A $\beta$  Fibril Assembly // *Molecules*. 2019, 25(1), p.77. [doi:10.3390/molecules25010077](https://doi.org/10.3390/molecules25010077)
  20. Pereira R., Silva A.M.S., Ribeiro D., Silva V.L.M, Fernandes E. Bis-chalcones: A review of synthetic methodologies and anti-inflammatory effects // *Eur. J Med Chem.* 2023, 252, p.115280. [doi:10.1016/j.ejmech.2023.115280](https://doi.org/10.1016/j.ejmech.2023.115280)
  21. Farooq S., Ngaini Z. Chalcone derived benzoheterodiazepines for medicinal applications: A Two-pot and one-pot synthetic approach // *J Hetero. Chem.*, 2021, 58 (10), p. 1914. <https://doi.org/10.1002/jhet.4337>
  22. Okolo E.N., Ugwu D.I., Ezema B.E. *et al.* New chalcone derivatives as potential antimicrobial and antioxidant agent // *Sci Rep*, 2021, 11, 21781. [doi.org/10.1038/s41598-021-01292-5](https://doi.org/10.1038/s41598-021-01292-5)
  23. Shaik A., Bhandare R.R., Palleapati K., Nissankararao S., Kancharlapalli V., Shaik S. Antimicrobial, Antioxidant, and Anticancer Activities of Some Novel Isoxazole Ring Containing Chalcone and Dihydropyrazole Derivatives // *Molecules*. 2020, 25(5), p.1047. [doi:10.3390/molecules25051047](https://doi.org/10.3390/molecules25051047)
  24. Elfi S.V.H., Widiastuti A.E.S. A green synthesis of chalcones as an antioxidant and anticancer // *IOP Conf. Ser. Mater. Sci. Eng.* 2018, 299, p.012077. [DOI 10.1088/1757-899X/299/1/012077](https://doi.org/10.1088/1757-899X/299/1/012077)
  25. Katharotiya P., Das S.P., Synthesis, characterization and investigation of chalcone as corrosion inhibitors for mild steel in hydrochloric acid // *Eur. Chem. Bull.*, 2021, 10(4), p. 199-204. [DOI: 10.17628/ecb.2021.10.199-204](https://doi.org/10.17628/ecb.2021.10.199-204)
  26. Abdul-Rida N.A., Sayyah M.H., Jaber Q.A.H. Synthesis, characterization, efficiency evaluation of some novel triazole derivatives as acid corrosion inhibitors // *Int. J. Corr. Scale Inhib.*, 2023, 12( 1), p.101. [doi:10.17675/2305-6894-2023-12-1-6](https://doi.org/10.17675/2305-6894-2023-12-1-6)
  27. Kyazimov V.M., Guseynov G.Z., Madji N.S., Mirzoyeva M.A., Nabiyeu O.G., Kyazimova G.S., Vahid-Zadeh L.K. Synthesis of  $\beta$ -Ketosulfides Based on Benzalacetone and Research Into Their Inhibitory Properties // *Chemical Problems*, 2023, 21, 2, p. 161. DOI: [10.32737/2221-8688-2023-2-161-167](https://doi.org/10.32737/2221-8688-2023-2-161-167).
  28. Nabeel A. Abdul-Rida, Zahraa M. Gareeb. Preparation and Characterization Biaryl aromatic compounds of the pyrimidine derivative by a Suzuki Coupling reaction and study their anti-cancer effect // *J. Phys.: Conf. Ser.*, 2020, 1664, p.012089. [DOI 10.1088/1742-6596/1664/1/012089](https://doi.org/10.1088/1742-6596/1664/1/012089)



29. Bahuguna A., Khan I., Bajpai V.K., Kang S.C., MTT assay to evaluate the cytotoxic potential of a drug // *Bangladesh Journal of Pharmacology*, 2017, 12(2), p.8. doi:10.3329/bjp.v12i2.30892
30. Baliyan S., Mukherjee R., Priyadarshini A., Vibhuti A., Gupta A., Pandey R.P. and Chang C.M., Determination of Antioxidants by DPPH Radical Scavenging Activity and Quantitative Phytochemical Analysis of *Ficus religiosa* // *Molecules*, 2022, 27(4), p.1326. doi:10.3390/molecules27041326
31. Rizvi S.M., Shakil S., Haneef M. A simple click by click protocol to perform docking: AutoDock 4.2 made easy for non-bioinformaticians // *EXCLI J.*, 2013, 12, p. 831-57.

## НОВЫЕ ПРОИЗВОДНЫЕ ХАЛКОНА КАК ПРОТИВОРАКОВЫЕ И АНТИОКСИДАНТНЫЕ АГЕНТЫ: СИНТЕЗ, ИССЛЕДОВАНИЕ МОЛЕКУЛЯРНОГО ДОКИНГА И БИОЛОГИЧЕСКАЯ ОЦЕНКА

Набилъ А. Абдул-Рида, Каутер М. Талиб

Кафедра химии, Университет Аль-Кадисия, Дивания, 58002, Ирак

Email: [nabeel.a.alradha@qu.edu.iq](mailto:nabeel.a.alradha@qu.edu.iq), [Kawthertallib196@gmail.com](mailto:Kawthertallib196@gmail.com)

**Аннотация:** В работе посредством конденсации Клайзена-Шмидта были синтезированы новые производные халкона, содержащие препарат баклофен, и оценены *in vitro* как противораковые и антиоксидантные средства. Синтезированные соединения были охарактеризованы спектрами ИК-Фурье,  $^1\text{H}$ -ЯМР,  $^{13}\text{C}$ -ЯМР и элементным анализом. Все продукты были проверены *in vitro* на клеточные линии HdFn и MCF-7. Результаты анализа цитотоксичности показали, что производные 5a и 5d продемонстрировали хорошее ингибирование клеточных линий MCF-7 со значениями IC50: 32,5 и 37,6 мкМ соответственно, тогда как 5a и 5c продемонстрировали приемлемое ингибирование HdFn со значениями IC50 - 76,7 и 78,6 мкМ, соответственно, по сравнению с Препарат Тамоксифен. Исследование молекулярного докинга целевых соединений подтвердило результаты теста на цитотоксичность. Кроме того, результаты ДФПГ-исследования выявили хорошую антиоксидантную активность производных 5a, 5b и 5d с процентами ингибирования 86.62, 81.38 и 76.42%, соответственно, по сравнению с аскорбиновой кислотой.

**Ключевые слова:** халкон, противораковое средство, антиоксидант, молекулярный докинг, цитотоксичность.

## XALKONUN YENİ TÖRƏMƏLƏRİ XƏRÇƏNGƏQARŞI VƏ ANTIOKSIDANT AGENTLƏR KİMİ: SİNTEZ, MOLEKULAR DOKİNG TƏDQİQATI VƏ BİOLOJİ QIYMƏTLƏNDİRİLMƏ

Nabeel A. Abdul-Rida, Kavter M. Talib

Kimya şöbəsi, Əl-Qadisiyyə Universiteti, Divaniyyə, 58002, İraq

Email: [nabeel.a.alradha@qu.edu.iq](mailto:nabeel.a.alradha@qu.edu.iq), [Kawthertallib196@gmail.com](mailto:Kawthertallib196@gmail.com)

**Xülasə:** İşdə, tərkibində baklofen preparatı olan bir sıra yeni xalkon törəmələri Claisen-Schmidt kondensasiyası ilə sintez edilmiş, xərcəng əleyhinə və antioksidant agentlər kimi *in vitro* qiymətləndirilmişdir. Yeni sintez edilmiş birləşmələr FT-İK,  $^1\text{H}$ -NMR,  $^{13}\text{C}$ -NMR spektrləri ilə xarakterizə edilmişdir və həmçinin element analizi aparılmışdır. Bütün alınan maddələr həm HdFn,

həm də MCF-7 hüceyrələrə qarşı *in vitro* olaraq yoxlanılmışdır. Sitotoksik analizinin nəticələri göstərdi ki, IC50 dəyərləri müvafiq olaraq 32,5 və 37,6  $\mu$ M olan 5a və 5d törəmələri MCF-7 hüceyrə sırasına qarşı yaxşı inhibisiya göstərilir, 5a və 5c birləşmələri isə IC50 üzrə 76,7 və 778  $\mu$ M qiymətlərinə malik olub Tamoksifen preparatı ilə müqayisədə HdFn hüceyrə sırasına qarşı qənaətbəxş inhibitorluq nümayiş etdirirlər. Alınmış birləşmələrin molekulyar dokinq tədqiqi onların sitotoksiklik testinin nəticələrini təsdiqlədi. Bundan əlavə, DPPH tədqiqatlarının nəticələri əsasında müəyyən edildi ki, 5a, 5c və 5d törəmələri müvafiq olaraq 86.62, 81.38 və 76.42 % inhibitorluq faizlərinə malikdirlər və askorbin turşusu ilə müqayisədə yaxşı antioksidant aktivliyi göstərilir.

**Açar sözləri:** Xalkon, xərçəngə qarşı, Antioksidant, Molekulyar Dokinq, Sitotoksik